Mark S. Shahin
Mark S. Shahin
Professor of Obstetrics & Gynecology. Jefferson University
Подтвержден адрес электронной почты в домене jefferson.edu
Niraparib in patients with newly diagnosed advanced ovarian cancer
A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ...
New England Journal of Medicine 381 (25), 2391-2402, 2019
Dostarlimab for primary advanced or recurrent endometrial cancer
MR Mirza, DM Chase, BM Slomovitz, R dePont Christensen, Z Novák, ...
New England Journal of Medicine 388 (23), 2145-2158, 2023
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
RE Buller, IB Runnebaum, BY Karlan, JA Horowitz, M Shahin, T Buekers, ...
Cancer gene therapy 9 (7), 553-566, 2002
Pembrolizumab plus chemotherapy in advanced endometrial cancer
RN Eskander, MW Sill, L Beffa, RG Moore, JM Hope, FB Musa, R Mannel, ...
New England Journal of Medicine 388 (23), 2159-2170, 2023
Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017
VN Giri, KE Knudsen, WK Kelly, W Abida, GL Andriole, CH Bangma, ...
Journal of Clinical Oncology 36 (4), 414, 2018
Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy
AK Sood, MS Shahin, JI Sorosky
Gynecologic oncology 83 (3), 599-600, 2001
The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma
MS Shahin, JH Hughes, AK Sood, RE Buller
Cancer: Interdisciplinary International Journal of the American Cancer …, 2000
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary …
RL Coleman, WE Brady, DS McMeekin, PG Rose, JT Soper, SS Lentz, ...
Gynecologic oncology 122 (1), 111-115, 2011
Anorectal dysfunction after surgical treatment for cervical cancer
AK Sood, I Nygaard, MS Shahin, JI Sorosky, SK Lutgendorf, SSC Rao
Journal of the American College of Surgeons 195 (4), 513-519, 2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500
RE Buller, MS Shahin, JA Horowitz, IB Runnebaum, V Mahavni, ...
Cancer gene therapy 9 (7), 567-572, 2002
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
I Vergote, G Scambia, DM O'Malley, B Van Calster, SY Park, ...
The lancet oncology 20 (6), 862-876, 2019
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study
RJ Schilder, WE Brady, HA Lankes, JV Fiorica, MS Shahin, XC Zhou, ...
Gynecologic oncology 127 (1), 70-74, 2012
Failure of BRCA1 dysfunction to alter ovarian cancer survival
RE Buller, MS Shahin, JP Geisler, M Zogg, BR De Young, CS Davis
Clinical cancer research 8 (5), 1196-1202, 2002
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology/gynecologic oncology group study (GOG-254)
JK Chan, W Brady, BJ Monk, J Brown, MS Shahin, PG Rose, JH Kim, ...
Gynecologic oncology 150 (2), 247-252, 2018
The p53 Mutational Spectrum Associated with BRCA1 Mutant Ovarian Cancer
RE Buller, TA Lallas, MS Shahin, AK Sood, M Hatterman-Zogg, ...
Clinical cancer research 7 (4), 831-838, 2001
A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study
TF Rocereto, WE Brady, MS Shahin, JS Hoffman, L Small, J Rotmensch, ...
Gynecologic oncology 116 (3), 332-334, 2010
A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study
BE Miller, JA Blessing, FB Stehman, MS Shahin, SD Yamada, AA Secord, ...
Gynecologic oncology 118 (2), 139-144, 2010
The Glutathione S-Transferase M1 Genotype in Ovarian Cancer
TA Lallas, SK McClain, MS Shahin, RE Buller
Cancer Epidemiology Biomarkers & Prevention 9 (6), 587-590, 2000
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic …
LP Martin, M Sill, MS Shahin, M Powell, P DiSilvestro, LM Landrum, ...
Gynecologic oncology 132 (3), 526-530, 2014
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study …
TJ Herzog, MW Sill, JL Walker, D O'Malley, M Shahin, K DeGeest, ...
Gynecologic oncology 120 (3), 454-458, 2011
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20